Rakovina Therapeutics Inc.

OTCPK:RKVT.F Stock Report

Market Cap: US$7.0m

Rakovina Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:RKVT.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 Dec 24BuyUS$5,225Michael LiggettIndividual50,000US$0.10
13 Dec 24BuyUS$3,801Jeffrey BachaIndividual90,192US$0.042
25 Oct 24BuyUS$4,757Alfredo De LucreziaIndividual88,000US$0.054
21 Oct 24BuyUS$3,361Alfredo De LucreziaIndividual62,000US$0.054
03 Oct 24BuyUS$2,031Jeffrey BachaIndividual25,000US$0.081
16 May 24BuyUS$1,744Mads DaugaardIndividual25,000US$0.07
19 Apr 24BuyUS$1,729Jeffrey BachaIndividual25,000US$0.069
05 Apr 24BuyUS$4,178Alfredo De LucreziaIndividual57,143US$0.074
28 Mar 24BuyUS$7,205Jeffrey BachaIndividual100,000US$0.072

Insider Trading Volume

Insider Buying: RKVT.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RKVT.F?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders8,212,8579.1%
Private Companies24,265,62526.9%
General Public57,810,69364%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.8%.

Top Shareholders

Top 7 shareholders own 35.97% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
26.9%
Edison Oncology Holding Corp.
24,265,625US$1.9m0%no data
5.77%
Alfredo De Lucrezia
5,212,500US$403.1k2.96%no data
2.09%
Jeffrey Bacha
1,885,357US$145.8k1.34%no data
0.69%
Dennis Brown
625,000US$48.3k0%no data
0.35%
David Hyman
315,000US$24.4k0%no data
0.14%
Mads Daugaard
125,000US$9.7k0%no data
0.055%
Benito Colangelo
50,000US$3.9k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/16 15:56
End of Day Share Price 2024/09/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rakovina Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution